据RNA World国际论坛组委会获悉，艾博生物制剂副总裁张志一博士确认参加于9月11-12日在上海举办的首届RNA World 2024，并发表主题演讲。

演讲题目：

Recent Advancement in Formulation Development of Thermostable mRNA-LNP Products

个人介绍：

Jerry Zhang joined the Suzhou Abogen Biosciences in May of 2020 and currently serves as the Vice President of Formulation leading the formulation, process development and tech transfer of mRNA-LNP products.

Dr. Zhang has 23 years of experiences in formulation development of sterile parenteral drug products including various complex injectables such as lipid nanoparticles, liposomes, nanoemulsions, polymeric nanoparticles and nanocrystal suspensions as well as lyophilized powders. Prior to joining Abogen, he worked for Hospira (now Pfizer), Daiichi Sankyo and Livzon Pharmaceutical Group as a Senior Research Pharmacist, Supervisor of Formulation R & D and Senior Director of Formulation, respectively. He also worked on mRNA-LNP formulations at Shire Human Genetic Therapies (now Takeda) and Arcturus Therapeutics to support preclinical studies.

Dr. Zhang holds a PhD in Bioorganic Chemistry from Kyushu University, a MS in Organic Chemistry and a BS in Chemistry from Fudan University. He completed his postdoctoral training at University of Notre Dame and Purdue University in liposome-based systems for triggered release and targeted delivery.